SEC Form 4 · accession 0001562180-18-003074
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Victor Sandor
Officer — Chief Medical Officer
Period of report
Jun 19, 2018
Accepted (ET)
Jun 21, 2018 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 19, 2018 | M | 77,576 | $3.65 | A | 287,662 | D | |
| Common StockF2 | Jun 19, 2018 | S | 77,576 | $18.76 | D | 210,086 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.65 | Jun 19, 2018 | M | 77,576 | D | — | Sep 22, 2024 | Common Stock | 77,576 | 279,259 | D |
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price of transactions made at prices from $18.75 to $18.845. Details of actual prices for shares sold are available from the Issuer upon request.
- F3The option vested in four equal annual installments beginning on September 22, 2015.